A share price of Castle Biosciences Inc [CSTL] is currently trading at $38.49, up 1.61%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CSTL shares have gain 13.37% over the last week, with a monthly amount glided 57.04%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Castle Biosciences Inc [NASDAQ: CSTL] stock has seen the most recent analyst activity on December 14, 2023, when Guggenheim initiated its Buy rating and assigned the stock a price target of $25. Previously, Scotiabank started tracking the stock with Sector Outperform rating on January 05, 2023, and set its price target to $54. On January 07, 2022, Stephens initiated with an Overweight rating and assigned a price target of $59 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $94 on April 30, 2021. KeyBanc Capital Markets initiated its recommendation with an Overweight and recommended $70 as its price target on November 10, 2020. Canaccord Genuity reiterated a Buy rating for this stock on December 27, 2019, and upped its price target to $35. In a note dated August 19, 2019, SVB Leerink initiated an Outperform rating and provided a target price of $28 on this stock.
Castle Biosciences Inc experienced fluctuations in its stock price throughout the past year between $14.59 and $38.15. Currently, Wall Street analysts expect the stock to reach $38 within the next 12 months. Castle Biosciences Inc [NASDAQ: CSTL] shares were valued at $38.49 at the most recent close of the market. An investor can expect a potential drop of -1.27% based on the average CSTL price forecast.
Analyzing the CSTL fundamentals
Trailing Twelve Months sales for Castle Biosciences Inc [NASDAQ:CSTL] were 343.53M which represents -3.19% decline. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.51 points at the first support level, and at 36.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.55, and for the 2nd resistance point, it is at 40.60.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Castle Biosciences Inc [NASDAQ:CSTL] is 6.47. Further, the Quick Ratio stands at 6.31, while the Cash Ratio is 1.62. Considering the valuation of this stock, the price to sales ratio is 3.27, the price to book ratio is 2.40.
Transactions by insiders
Recent insider trading involved TOBIN JUVENAL, Officer, that happened on Nov 24 ’25 when 1301.0 shares were purchased. Chief Commercial Officer, Juvenal Tobin W completed a deal on Nov 20 ’25 to sell 4693.0 shares. Meanwhile, Pres. & Chief Exec. Officer MAETZOLD DEREK J sold 2678.0 shares on Nov 18 ’25.
